January 09, 2026

A Rare Case of Acute Hemolysis After Rasburicase Infusion

A case study highlights the critical need for awareness of G6PD deficiency in CLL patients on venetoclax, following a rare hemolytic reaction to rasburicase.

JADPRO

January 09, 2026

Integrative Oncology Models of Care: Practice Patterns From NCCN Member Institutions

Integrative oncology is gaining traction as patients increasingly seek complementary therapies to enhance their cancer care and quality of life.

JADPRO

January 09, 2026

Clinical Posters From JADPRO Live 2025

Discover how structured onboarding and APP-led initiatives are transforming oncology care while improving patient outcomes.

JADPRO

January 06, 2026

IMvigor011 Subgroup Analysis: Role of ctDNA in Guiding Adjuvant Treatment for Muscle-Invasive Bladder Cancer

Circulating tumor DNA (ctDNA) status after radical cystectomy may be able to guide adjuvant treatment decisions for patients with muscle-invasive bladder cancer, according to phase III data.

The ASCO Post

January 06, 2026

AI Tops Density in Predicting Breast Cancer Risk

An image-only artificial intelligence (AI) model for predicting the 5-year risk of breast cancer provided stronger and more precise risk stratification than breast density assessment, according to a n...

The ASCO Post

January 02, 2026

New Trial Tests Gabapentin As Treatment for Mucositis, Replacing Opioids

A new trial available at Roswell Park Comprehensive Cancer Center, organized by the Alliance for Clinical Trials in Oncology Foundation, is looking to determine the efficacy of using gabapentin for pain mitigation.

Roswell Park Comprehensive Cancer Center

January 02, 2026

Which First-Line Systemic Therapy Balances Survival and Quality of Life in Advanced Hepatocellular Carcinoma?

A network meta-analysis reported in JAMA Oncology found that among first-line systemic therapy options, immunotherapy-based combinations offered the most favorable therapeutic balance between survival...

The ASCO Post

January 02, 2026

Adding Dendritic Cell Vaccination to Hepatocellular Carcinoma Therapy

In patients with intermediate-stage hepatocellular carcinoma, can the addition of a vaccine of dendritic cells to transarterial chemoembolization (TACE) and preconditioning cyclophosphamide result in ...

The ASCO Post

January 02, 2026

Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable HCC

The expanded indication marks the first and only radioembolization therapy in the United States approved to treat both unresectable hepatocellular carcinoma (HCC) and colorectal cancer liver metastase...

The ASCO Post